Oral Immune-Related Adverse Events - Current Concepts and their Management

被引：3
作者：
Asan, Mohamed Faizal [1 ]
Castelino, Renita Lorina [1 ]
Babu, Subhas G. [1 ]
Rao, Kumuda [1 ]
Pandita, Vaibhav [1 ]
机构：
[1] Nitte Deemed be Univ, AB Shetty Mem Inst Dent Sci, Dept Oral Med & Radiol, Mangalore, Karnataka, India
来源：
ASIA-PACIFIC JOURNAL OF ONCOLOGY NURSING | 2021年 / 8卷 / 06期
关键词：
Immune-related adverse events; immunotherapy; oral mucositis; quality of life; LEVEL LASER THERAPY; CHECKPOINT INHIBITORS; LICHENOID REACTIONS; CANCER; ANTI-PD-1; SAFETY; PEMBROLIZUMAB; IMMUNOTHERAPY; IPILIMUMAB; NIVOLUMAB;
D O I：
10.4103/apjon.apjon-2136
中图分类号：
R47 [护理学];
学科分类号：
1011 ;
摘要：
Recent advent of immune checkpoint inhibitors (ICIs) have made significant improvement in the treatment outcome of cancer patients. They are also known to increase the overall survival in many malignancies. They target key immune checkpoints, acting on the cytotoxic T-lymphocyte antigen-4, programmed death-1 (PD-1), and PD-1 ligand 1 pathways. ICIs are effective in cancer therapy, but also possess various adverse effects that are termed together as immune-related adverse events (irAEs). Information focusing only on the oral reactions of irAEs is scanty in the literature. Therefore, we performed a computerized database search in PubMed and Google Scholar to identify and collect data regarding the oral adverse effects of ICIs. The early recognition of oral irAEs and appropriative intervention may help in improving the quality of life in patients. This paper presents a brief review of oral irAEs and their management.
引用
收藏
页码：604 / 609
页数：6
相关论文
共 50 条
  • [1] Long-term survival of a randomized phase III trial of head and neck cancer patients receiving concurrent chemoradiation therapy with or without low-level laser therapy (LLLT) to prevent oral mucositis
    Antunes, Heliton S.
    Herchenhorn, Daniel
    Small, Isabele A.
    Araujo, Carlos M. M.
    Pais Viegas, Celia Maria
    Ramos, Gabriela de Assis
    Dias, Fernando L.
    Ferreira, Carlos G.
    [J]. ORAL ONCOLOGY, 2017, 71 : 11 - 15
  • [2] Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer
    Borghaei, H.
    Paz-Ares, L.
    Horn, L.
    Spigel, D. R.
    Steins, M.
    Ready, N. E.
    Chow, L. Q.
    Vokes, E. E.
    Felip, E.
    Holgado, E.
    Barlesi, F.
    Kohlhaeufl, M.
    Arrieta, O.
    Burgio, M. A.
    Fayette, J.
    Lena, H.
    Poddubskaya, E.
    Gerber, D. E.
    Gettinger, S. N.
    Rudin, C. M.
    Rizvi, N.
    Crino, L.
    Blumenschein, G. R.
    Antonia, S. J.
    Dorange, C.
    Harbison, C. T.
    Finckenstein, F. Graf
    Brahmer, J. R.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2015, 373 (17) : 1627 - 1639
  • [3] The pathogenesis of mucositis: updated perspectives and emerging targets
    Bowen, J.
    Al-Dasooqi, N.
    Bossi, P.
    Wardill, H.
    van Sebille, Y.
    Al-Azri, A.
    Bateman, E.
    Correa, M. E.
    Raber-Durlacher, J.
    Kandwal, A.
    Mayo, B.
    Nair, R. G.
    Stringer, A.
    ten Bohmer, K.
    Thorpe, D.
    Lalla, R. V.
    Sonis, S.
    Cheng, K.
    Elad, S.
    [J]. SUPPORTIVE CARE IN CANCER, 2019, 27 (10) : 4023 - 4033
  • [4] Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline
    Brahmer, Julie R.
    Lacchetti, Christina
    Schneider, Bryan J.
    Atkins, Michael B.
    Brassil, Kelly J.
    Caterino, Jeffrey M.
    Chau, Ian
    Ernstoff, Marc S.
    Gardner, Jennifer M.
    Ginex, Pamela
    Hallmeyer, Sigrun
    Chakrabarty, Jennifer Holter
    Leighl, Natasha B.
    Mammen, Jennifer S.
    McDermott, David F.
    Naing, Aung
    Nastoupil, Loretta J.
    Phillips, Tanyanika
    Porter, Laura D.
    Puzanov, Igor
    Reichner, Cristina A.
    Santomasso, Bianca D.
    Seigel, Carole
    Spira, Alexander
    Suarez-Almazor, Maria E.
    Wang, Yinghong
    Weber, Jeffrey S.
    Wolchok, Jedd D.
    Thompson, John A.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (17) : 1714 - +
  • [5] Severe immune mucositis and esophagitis in metastatic squamous carcinoma of the larynx associated with pembrolizumab
    Brand, Fanny Zulay Acero
    Suter, Nicolas
    Adam, Jean-Philippe
    Faulques, Bernard
    Maietta, Antonio
    Soulieres, Denis
    Blais, Normand
    [J]. JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2018, 6
  • [6] Incidence of and risk factors for development of oral mucositis in outpatients undergoing cancer chemotherapy
    Cakmak, Seher
    Nural, Nesrin
    [J]. INTERNATIONAL JOURNAL OF NURSING PRACTICE, 2019, 25 (01)
  • [7] Cecchi C, CLIN LUNG CANCER, V2021
  • [8] Choi J, 2020, IMMUNE NETW, V20
  • [9] Immune-Related Adverse Events (irAEs): Diagnosis, Management, and Clinical Pearls
    Darnell, Eli P.
    Mooradian, Meghan J.
    Baruch, Erez N.
    Yilmaz, Melis
    Reynolds, Kerry L.
    [J]. CURRENT ONCOLOGY REPORTS, 2020, 22 (04)
  • [10] Prevention and Treatment of Chemotherapy and Radiotherapy Induced Oral Mucositis
    Daugelaite, Goda
    Uzkuraityte, Kriste
    Jagelaviciene, Egle
    Filipauskas, Aleksas
    [J]. MEDICINA-LITHUANIA, 2019, 55 (02):
12345